Zomedica (ZOM) 10-Q 11 Aug 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 11, 2021
Document Information [Line Items]
Entity Central Index Key	0001684144
Entity Registrant Name	Zomedica Corp.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-38298
Entity Incorporation, State or Country Code	A0
Entity Address, Address Line One	100 Phoenix Drive, Suite 125
Entity Address, City or Town	Ann Arbor
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48108
City Area Code	734
Local Phone Number	369-2555
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Title of 12(b) Security	Common Shares, without par value
Trading Symbol	ZOM
Security Exchange Name	NYSEAMER
Entity Common Stock, Shares Outstanding		979,728,168

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 276,209,816	$ 61,991,703
Inventory	793,898	0
Prepaid expenses and deposits	222,478	1,727,814
Trade receivables	4,264	0
Other receivables	268,501	146,207
Total current assets	277,498,957	63,865,724
Prepaid expenses and deposits	1,081,083	13,924
Property and equipment, net	265,845	583,007
Right-of-use asset	1,132,548	1,318,716
Intangible assets, net	373,851	362,663
Total assets	280,352,284	66,144,034
Current liabilities
Accounts payable and accrued liabilities	3,095,203	1,248,628
Current portion of debt obligations	0	527,360
Current portion of lease liabilities	302,112	252,788
Total current liabilities	3,397,315	2,028,776
Lease obligations	886,956	1,087,998
Total liabilities	4,284,271	3,116,774
Commitments and contingencies (Note 13)
Mezzanine equity:
Series 1 preferred shares, no par value; 20 shares authorized 0 and 12 Series 1 preferred shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	0	11,961,397
Shareholders' equity
Unlimited common shares, no par value; 977,950,993 and 642,036,228 issued and outstanding at June 30, 2021 and December 31, 2020, respectively	380,222,091	104,783,612
Common shares subscribed	0	459,600
Additional paid-in capital	5,601,641	14,792,276
Accumulated deficit	(109,755,719)	(68,969,625)
Total shareholders' equity	276,068,013	51,065,863
Total liabilities, mezzanine equity and shareholders' equity	$ 280,352,284	$ 66,144,034

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Mezzanine equity, par value (in dollars per share)	$ 0	$ 0
Mezzanine equity, shares authorized (in shares)	20	20
Mezzanine equity, shares issued (in shares)	0	12
Mezzanine equity, shares outstanding (in shares)	0	12
Capital stock, no par value (in dollars per share)	$ 0	$ 0
Capital stock, issued (in shares)	977,950,993	642,036,228
Capital stock, outstanding (in shares)	977,950,993	642,036,228
Capital stock, shares authorized	Unlimited	Unlimited

Condensed Consolidated Statemen

Condensed Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net revenue	$ 15,693	$ 0	$ 29,817	$ 0
Cost of revenue	35,876	0	41,533	0
Gross profit	(20,183)	0	(11,716)	0
Expenses
Research and development	270,674	3,908,171	683,802	4,503,570
Selling, general and administrative	5,037,729	1,394,374	8,505,399	3,132,481
Loss from operations	(5,328,586)	(5,302,545)	(9,200,917)	(7,636,051)
Interest income	(112,107)	(247)	(167,254)	(328)
Interest expense	6,054	0	6,054	732
(Gain) Loss on disposal of assets	(116)	0	242,947	128,931
Gain on extinguishment of debt	(533,414)	0	(533,414)	0
Other loss (income)	22,196	0	(1,881)	(5,500)
Foreign exchange loss (gain)	(525)	5,691	122	(1,279)
Loss before income taxes	(4,710,674)	(5,307,989)	(8,747,491)	(7,758,607)
Income tax expense	0	0	0	0
Net loss and comprehensive loss	$ (4,710,674)	$ (5,307,989)	$ (8,747,491)	$ (7,758,607)
Weighted average number of common shares - basic and diluted (in shares)	973,656,518	214,830,818	932,959,287	166,814,645
Loss per share - basic and diluted (Note 18) (in dollars per share)	$ (0.005)	$ (0.02)	$ (0.01)	$ (0.05)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Common Stock Subscribed [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019	12	108,038,398
Balance at Dec. 31, 2019	$ 11,961,397	$ 38,566,820	$ 0	$ 3,625,083	$ (52,057,841)	$ 2,095,459
Stock and warrant issuance for financing (in shares)		175,330,001
Stock issuance for financing		$ 15,984,325	1,465,500	10,514,458	0	27,964,283
Stock issuance costs		(1,755,376)	0	(1,084,024)	0	(2,839,400)
Stock-based compensation		$ 0	0	290,866		290,866
Stock issued from warrant exercises (in shares)		65,509,055
Stock issued from warrant exercises		$ 13,607,631
Stock issued from stock option exercises						0
Net loss		0	0	0	(7,758,607)	(7,758,607)
Stock, warrants and pre-funded warrants issuance for financing		15,984,325	1,465,500	10,514,458	0	27,964,283
Placement agent warrants		$ (154,767)	0	154,767	0	0
Stock issued from exercise of warrants and prefunded warrants (in shares)		77,671,547
Stock issued from exercise of warrants and prefunded warrants		$ 14,687,920	0	(4,861,560)	0	9,826,360
Balance (in shares) at Jun. 30, 2020	12	361,039,946
Balance at Jun. 30, 2020	$ 11,961,397	$ 67,328,922	1,465,500	8,639,590	(59,816,448)	29,578,961
Balance (in shares) at Mar. 31, 2020	12	128,871,732
Balance at Mar. 31, 2020	$ 11,961,397	$ 39,998,442	0	4,500,263	(54,508,459)	1,951,643
Stock and warrant issuance for financing (in shares)		154,496,667
Stock issuance for financing		$ 14,278,670	1,465,500	9,720,113	0	25,464,283
Stock issuance costs		(1,517,159)	0	(974,021)	0	(2,491,180)
Stock-based compensation		0	0	135,844	0	135,844
Stock issued from stock option exercises						0
Net loss		0		0	(5,307,989)	(5,307,989)
Stock, warrants and pre-funded warrants issuance for financing		14,278,670	1,465,500	9,720,113	0	25,464,283
Placement agent warrants		$ (118,951)	0	118,951	0	0
Stock issued from exercise of warrants and prefunded warrants (in shares)		77,671,547
Stock issued from exercise of warrants and prefunded warrants		$ 14,687,920		(4,861,560)		9,826,360
Balance (in shares) at Jun. 30, 2020	12	361,039,946
Balance at Jun. 30, 2020	$ 11,961,397	$ 67,328,922	1,465,500	8,639,590	(59,816,448)	29,578,961
Balance (in shares) at Dec. 31, 2020	0	642,036,228
Balance at Dec. 31, 2020	$ 0	$ 104,783,612	459,600	14,792,276	(68,969,625)	51,065,863
Stock and warrant issuance for financing (in shares)	0	105,013,158
Stock issuance for financing	$ 0	$ 199,525,000	0	0	0	199,525,000
Stock issuance costs	0	(14,280,914)	0	0	0	(14,280,914)
Stock-based compensation	$ 0	$ 0	0	3,064,818		3,064,818
Stock issued from warrant exercises (in shares)	0	200,951,905
Stock issued from warrant exercises	$ 0	$ 44,082,183	(459,600)	(11,511,046)	0	$ 32,111,537
Stock issued from stock option exercises (in shares)	0	5,230,601				5,230,601
Stock issued from stock option exercises	$ 0	$ 2,112,210		(744,407)		$ 1,367,803
Preferred share exchange (in shares)	0	24,719,101
Preferred share exchange	$ 0	$ 44,000,000		0	(32,038,603)	11,961,397
Net loss	0	0	0	0	(8,747,491)	(8,747,491)
Stock, warrants and pre-funded warrants issuance for financing	$ 0	$ 199,525,000	0	0	0	199,525,000
Balance (in shares) at Jun. 30, 2021	0	977,950,993
Balance at Jun. 30, 2021	$ 0	$ 380,222,091	0	5,601,641	(109,755,719)	276,068,013
Balance (in shares) at Mar. 31, 2021	0	972,092,308
Balance at Mar. 31, 2021	$ 0	$ 377,970,846	0	4,602,089	(105,045,045)	277,527,890
Stock issuance costs	0	453	0	0	0	453
Stock-based compensation	$ 0	$ 0	0	1,782,076	0	1,782,076
Stock issued from warrant exercises (in shares)	0	628,084
Stock issued from warrant exercises	$ 0	$ 138,582	0	(38,117)	0	100,465
Stock issued from stock option exercises (in shares)	0	5,230,601
Stock issued from stock option exercises	$ 0	$ 2,112,210	0	(744,407)	0	1,367,803
Net loss	$ 0	$ 0	0	0	(4,710,674)	(4,710,674)
Balance (in shares) at Jun. 30, 2021	0	977,950,993
Balance at Jun. 30, 2021	$ 0	$ 380,222,091	$ 0	$ 5,601,641	$ (109,755,719)	$ 276,068,013

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (8,747,491)	$ (7,758,607)
Adjustments for
Depreciation	(114,724)	(154,275)
Amortization - intangible assets	89,468	90,025
Loss on disposal of property and equipment	242,947	69,834
Loss on other assets	5,323	59,097
Gain on extinguishment of debt	(533,414)	0
Stock-based compensation	3,064,818	290,866
Non-cash portion of rent expense	35,182	52,480
Change in non-cash operating working capital
Purchased inventory	(793,898)	0
Prepaid expenses and deposits	437,302	(114,878)
Trade receivable	(4,264)	67,908
Other receivables	(133,114)	78,762
Accounts payable and accrued liabilities	1,846,575	(883,414)
Net cash used in operating activities	(4,375,842)	(7,893,652)
Cash flows from investing activities:
Cash from sale of property and equipment	75	5,400
Investment in intangibles	(98,710)	0
Investment in property and equipment	(42,643)	0
Cash from lease cancellation or modification	0	1,002,113
Net cash (used in) provided by investing activities	(141,278)	1,007,513
Cash flows from financing activities:
Proceeds from issuance of common shares, warrants and pre-funded warrants	199,525,000	26,498,783
Cash received from warrant exercises	32,111,536	9,826,359
Cash received from stock option exercises	1,367,802	0
Cash received from shares to be issued	0	1,465,500
Cash paid on stock issuance costs	(14,269,105)	(2,839,400)
Cash received for government loan	0	527,360
Net cash provided by financing activities	218,735,233	35,478,602
Increase in cash and cash equivalents	214,218,113	28,592,463
Cash and cash equivalents, beginning of period	61,991,703	510,586
Cash and cash equivalents, end of period	276,209,816	29,103,049
Supplemental cash flow information:
Interest paid	0	651
Interest received	$ (111,567)	$ 0

Note 1 - Nature of Operations

Note 1 - Nature of Operations	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	1. The Company is a veterinary health company creating point-of-care diagnostics products for dogs and cats, that focuses on the needs of the veterinarians themselves. The impact of the novel strain of coronavirus ( COVID- 19 ) The outbreak of the novel strain of coronavirus, specifically identified as “COVID- 19”, March 2020. The COVID- 19 five five may 19 may 19,

Note 2 - Basis of Preparation

Note 2 - Basis of Preparation	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Basis of Accounting [Text Block]	2. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for the presentation of interim financial statements and with the instructions to Form 10 10 X. not three six June 30, 2021, not may December 31, 2021. 2; 10 December 31, 2020. December 31, 2020,

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Estimates and assumptions In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not may may may Inventories Inventories are stated at the lower of cost or net realizable value. The Company utilizes specific identification to track inventory costs. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not Revenue recognition The Company enters into agreements which may The Company allocates revenue to each performance obligation in proportion to the relative standalone selling prices and recognizes revenue when control of the related goods or services is transferred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately. The Company's contracts with customers are generally comprised of purchase orders for the sale of the point of care diagnostic instrument, consumable products, and warranties, or some variation thereof. The instrument and consumables each represent a single performance obligation when sold separately, that is satisfied at a point in time upon transfer of control of the product to the customer which is typically upon receipt of the goods by the customer. The warranties are also a separate performance obligation, whereby revenue is recognized over time. Sales are recorded net of sales tax. Sales tax is charged on sales to end users and remitted to the appropriate state authority. Accounts receivable are recorded at net realizable value and have payment terms of 30 Cost of revenue Cost of goods sold consists of materials, and shipping costs incurred internally to produce and receive the products. Shipping and handling costs incurred by the Company are included in cost of goods sold. Comparative figures Certain prior year amounts have been reclassified to conform to the current year presentation. The change in presentation had no three six June 30, 2020. not

Note 4 - Prepaid Expenses, Depo

Note 4 - Prepaid Expenses, Deposits, and Deferred Financing Costs	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Prepaid Rent [Text Block]	4. June 30, December 31, 2021 2020 Deposits (i) $ 1,173,689 $ 1,469,043 Prepaid marketing 13,993 26,330 Prepaid insurance 33,995 184,154 Other (ii) 81,884 62,211 Total $ 1,303,561 $ 1,741,738 (i) Deposits include payments made to vendors in advance and are primarily associated with inventory, warranties, and research activity. As of June 30, 2021, December 31, 2020, (ii) Other is comprised of deferred financing costs, subscription payments, utilities, travel costs, and software licensing. As of June 30, 2021, December 31, 2020,

Note 5 - Property and Equipment

Note 5 - Property and Equipment	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. June 30, December 31, 2021 2020 Computer equipment $ 409,825 $ 364,165 Furniture and equipment 110,244 121,281 Laboratory equipment 225,330 234,087 Leasehold improvements 272,192 571,460 1,017,591 1,290,993 Accumulated depreciation and amortization 751,745 707,986 Net property and equipment $ 265,845 $ 583,007 Depreciation expense for the three June 30, 2021 2020 $55,398 six June 30, 2021 2020

Note 6 - Intangible Assets

Note 6 - Intangible Assets	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	6. June 30, December 31, 2021 2020 Computer software $ 28,097 $ 22,882 Trademarks 16,236 16,236 Website 609,121 513,680 653,454 552,798 Accumulated amortization 279,603 190,135 Net intangibles $ 373,851 $ 362,663 Amortization expense for the three June 30, 2021 2020 six June 30, 2021 2020

Note 7 - Leases

Note 7 - Leases	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	7. On February 1, 2020, February 1, 2020, January 31, 2025, On February 1, 2020, On February 1, 2021, February 1, 2021, January 31, 2025, first two On February 1, 2021, During the three six June 30, 2021, During the three six June 30, 2020, $38,992 $124,060 $137,630 June 30, 2021 December 31, 2020 Right-of-use asset Cost Aggregate lease commitments $ 1,387,655 $ 2,067,505 Less: impact of present value and lease modification (129,392 ) (513,894 ) Balance 1,258,263 1,553,611 Reduction in right-of-use asset Straight line amortization 142,116 379,043 Interest (16,400 ) (144,148 ) Balance 125,716 234,895 Net book value $ 1,132,548 $ 1,318,716 Lease liabilities Additions $ 1,281,609 $ 1,553,611 Payments (108,941 ) (356,972 ) Interest 16,400 144,147 Total lease liabilities $ 1,189,068 $ 1,340,786 Current portion of lease liabilities 302,112 252,788 Long term portion of lease liabilities 886,956 1,087,998 Total lease liabilities $ 1,189,068 $ 1,340,786 Total remaining undiscounted lease liabilities related to the above lease are as follows: 2021 - remainder balance $ 169,728 $ 400,133 2022 348,790 412,137 2023 359,254 424,501 2024 370,031 437,236 2025 30,911 36,526 Total $ 1,278,714 $ 1,710,533

Note 8 - Loan Arrangements

Note 8 - Loan Arrangements	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	8. On October 18, 2017, may $5,000,000, five 5 may one one not two may fourteen June 30, 2021, The Coronavirus Aid, Relief, and Economic Security Act, or (“CARES”) Act, was signed into law on March 27, 2020, $2.0 19 100% $10 2.5x not Under the Program, the borrower is eligible for loan forgiveness up to the amount the borrower spends on certain eligible costs during the 8 25% not 1% 18 24 54 24 In April 2020, June 13, 2021

Note 9 - Preferred Shares

Note 9 - Preferred Shares	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Preferred Stock [Text Block]	9. The Company is authorized to issue up to 20 shares of its Series 1 1 not not 1 not 9 1 1 9 1 Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series 1 1 1 In the event of a fundamental transaction (defined to include an amalgamation, merger or other business combination transaction involving our company in which the shareholders do not 50% may third 1 1 1 5.0 9.0 Issued and outstanding preferred stock: Number of preferred Preferred stock stock amount Balance at December 31, 2019 12 $ 11,961,397 Balance at December 31, 2020 12 11,961,397 Stock redemption (12 ) (11,961,397 ) Balance at June 30, 2021 - $ - The Company exchanged the issued and outstanding shares of its Series 1 March 7, 2021,

Note 10 - Common Shares

Note 10 - Common Shares	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. The Company is authorized to issue an unlimited number of common shares, without par value. Issued and outstanding common shares: Number of common stock Common stock amount Balance at December 31, 2019 108,038,398 $ 38,566,820 Stock issued from financing (i,ii,iii) 175,330,001 14,074,182 Stock issued from the financing and exercise of prefunded warrants (iv) 12,162,492 1,080,289 Stock issued from the exercise of warrants 65,509,055 13,607,631 Balance at June 30, 2020 361,039,946 67,328,922 Balance at December 31, 2020 642,036,228 $ 104,783,612 Stock issued from financing (v) 105,013,158 185,244,086 Stock issued from exercises of warrants 200,951,905 44,082,183 Stock issued from exercises of options (Note 11) 5,230,601 2,112,210 Stock issued from preferred share redemption (Note 9) 24,719,101 44,000,000 Balance at June 30, 2021 977,950,993 $ 380,222,091 (i) On February 14, 2020, six 20,833,334 The Company raised $2,500,000 in gross proceeds as part of the RDO. The Company recorded $1,705,655 as the value of common shares under common shares and $794,345 as the value of Series A Warrants under additional paid-in-capital in the consolidated statements of shareholders’ equity. The direct cash costs related to the issuance of the common shares and warrants issued in February 2020 (ii) On April 9, 2020, one shares,16,666,667 The Company raised $4,000,000 in gross proceeds in the CMPO. The Company recorded $2,942,248 as the value of common shares under common stock and $1,057,752 as the value of Series B Warrants under additional paid-in-capital in the consolidated statements of shareholders’ equity. The direct cash costs related to the issuance of the common shares and warrants issued in April (iii) On May 29, 2020 not The Company raised $19,998,783 in gross proceeds as part of the public offering. The Company recorded $11,336,422 as the value of common shares under common stock, $1,080,289 as the value of the pre-funded warrants and $7,582,072 as the value of Series C Warrants under additional paid-in-capital in the consolidated statements of shareholders’ equity. The direct cash costs related to the issuance of the common shares, Series C pre-funded warrants and Series C Warrants issued in May (iv) All Series C pre-funded warrants were exercised in June 2020. (v) On February 8, 2021, 30 The Company raised $199,525,000 in gross proceeds as part of the offering. The Company recorded $199,525,000 as the value of common shares under common shares. The direct cash costs related to the issuance of the common shares and warrants issued in February 2021 (vi) Cumulative warrant exercises as of the six June 30, 2021 Warrant series Warrants exercised Amount Series A 21,677,084 $ 4,293,229 Series B 17,969,833 2,695,475 Series C 133,056,833 19,958,525 Series D 187,269,000 29,963,040 Subtotal 359,972,750 56,910,269 Common stock subscribed - (459,600 ) Total 359,972,750 $ 56,450,669

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	11. During the three six June 30, 2021, four ten three six June 30, 2021, 5,774,351 June 30, 2021, July 1, 2021. During the three six June 30, 2020, four five three six June 30, 2020, The continuity of stock options are as follows: Number of Options Weighted Avg Exercise Price Balance at December 31, 2020 39,604,515 $ 0.36 Stock options granted 9,200,000 $ 0.95 Stock options exercised (5,774,351 ) $ 0.26 Stock options forfeited (4,509,015 ) $ 1.36 Stock options cancelled (200,000 ) $ 1.87 Balance at June 30, 2021 38,321,149 $ 0.23 Vested at June 30, 2021 10,342,149 $ 0.27 As of June 30, 2021, Grant date Exercise price Number of options issued and outstanding Number of vested options outstanding Number of unvested options outstanding Weighted Avg Remaining Life outstanding (years) March 14, 2020 0.19 3,253,557 1,900,807 1,352,750 3.71 July 9, 2020 0.18 175,000 43,750 131,250 4.03 August 25, 2020 0.13 38,425 8,425 30,000 4.16 September 29, 2020 0.11 225,000 225,000 - 4.16 October 1, 2020 0.11 266,667 41,667 225,000 4.16 October 20, 2020 0.09 40,000 10,000 30,000 4.31 December 31, 2020 0.23 25,322,500 7,762,500 17,560,000 9.51 February 26, 2021 1.87 600,000 150,000 450,000 9.67 March 1, 2021 2.06 200,000 50,000 150,000 9.67 March 8, 2021 1.88 200,000 50,000 150,000 9.69 March 15, 2021 2.49 200,000 50,000 150,000 9.71 May 12, 2021 0.78 4,600,000 - 4,600,000 9.87 May 14, 2021 0.78 3,200,000 50,000 3,150,000 9.88 Balance at June 30, 2021 38,321,149 10,342,149 27,979,000 The Company calculates volatility of stock-based compensation using the historical price of the Company’s stock. An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options. The fair value of options granted during the three six June 30, 2021, 2020 March 14, 2020 February 26, 2021 March 1, 2021 March 8, 2021 Volatility 87 % 117 % 117 % 117 % Risk-free interest rate 0.49 % 0.95 % 0.92 % 1.07 % Expected life (years) 5 10 10 10 Dividend yield 0 % 0 % 0 % 0 % Common share price $ 0.18 $ 1.87 $ 2.06 $ 1.88 Strike price $ 0.19 $ 1.87 $ 2.06 $ 1.88 Forfeiture rate 0 0 0 0 March 15, 2021 May 12, 2021 Volatility 117 % 118 % Risk-free interest rate 1.06 % 1.11 % Expected life (years) 10 6.21 - 6.22 Dividend yield 0 % 0 % Common share price $ 2.49 $ 0.78 Strike price $ 2.49 $ 0.78 Forfeiture rate 0 0 The Company recorded $1,782,076 and $3,064,818 of stock-based compensation for the three six June 30, 2021. three six June 30, 2020. For the three six June 30, 2021, three six June 30, 2020, zero

Note 12 - Warrants

Note 12 - Warrants	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Stockholders' Equity Warrants Note Disclosure [Text Block]	12. The Company calculates volatility of warrants based on the historical price of the Company’s stock. An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options. In connection with the February 14, 2020 five one one $.20 In connection with the April 9, 2020 five one one In connection with the May 29, 2020 two one December 31, 2020, In connection with the July 7, 2020 two one December 31, 2020, As of June 30, 2021, Original Issue date Exercise Price Warrants Outstanding Weighted Average Remaining Life February 14, 2020 0.20 - - February 14, 2020 0.15 197,917 3.62 April 9, 2020 0.15 363,501 3.78 May 29, 2020 0.15 276,500 0.91 July 7, 2020 0.16 231,000 1.02 Balance at June 30, 2021 1,068,918

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	13. On May 10, 2018, ● 1 st ● 2 nd 10 As of June 30, 2021, none not June 30, 2021, December 31, 2020. From time to time, the Company may June 30, 2021, August 11, 2021, not On November 1, 2019, 1:19 01108 November 22, 2019. January 21, 2020, February 11, 2020, February 25, 2020. September 30, 2020, October 14, 2020, May 10, 2021, no not Under the terms of the Development and Supply Agreement, dated November 26, 2018, third

Note 14 - Financial Instruments

Note 14 - Financial Instruments	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	14. (a) Fair values The Company follows ASC topic 820, 820 820 three three three Level 1 Level 2 1 Level 3 The categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The carrying values of cash, trade and other receivable, accounts payable and accrued liabilities and shareholder loans payable approximates their fair values because of the short-term nature of these instruments. The following are the contractual maturities of the undiscounted cash flows of financial liabilities as at March 31, 2021 December 31, 2020: June 30, 2021 Less than 3 6 6 9 9 months Greater than 3 months months months 1 year 1 year Total Third parties Accounts payable and accrued liabilities $ 3,095,203 $ - $ - $ - $ - $ 3,095,203 Lease obligations 73,362 74,089 76,524 78,137 886,956 1,189,068 $ 3,168,565 $ 74,089 $ 76,524 $ 78,137 $ 886,956 $ 4,284,271 December 31, 2020 Less than 3 6 6 9 9 months Greater than 3 months months months 1 year 1 year Total Third parties Accounts payable and accrued liabilities $ 1,248,628 $ - $ - $ - $ - $ 1,248,628 Debt obligations 527,360 - - - - 527,360 Lease obligations 59,662 62,463 64,356 66,307 1,087,998 1,340,786 $ 1,835,650 $ 62,463 $ 64,356 $ 66,307 $ 1,087,998 $ 3,116,774

Note 15 - Segment Information

Note 15 - Segment Information	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	15. The Company's operations comprise a single reportable segment engaged in the research, development targeting health and wellness solutions for the companion animal. As the operations comprise a single reportable segment, amounts disclosed in the financial statements for loss for the period, depreciation and total assets also represent segmented amounts. In addition, all the Company's long-lived assets are in the United States of America (“US”). June 30, December 31, 2021 2020 Canada $ 249,894,586 $ 53,160,701 US 30,457,698 12,983,333 Total assets $ 280,352,284 $ 66,144,034 Total US property and equipment $ 265,845 $ 583,007 Total US right-of-use asset 1,132,548 1,318,716 $ 1,398,393 $ 1,901,723

Note 16 - Loss Per Share

Note 16 - Loss Per Share	6 Months Ended
	Jun. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	16. For the three months ended June 30 For the six months ended June 30 2021 2020 2021 2020 Numerator Net loss for the period $ (4,710,674 ) $ (5,307,989 ) $ (8,747,491 ) $ (7,758,607 ) Charge to retained earnings for preferred share exchange - (32,038,603 ) - Loss attributable to common shareholders (4,710,674 ) (5,307,989 ) (40,786,094 ) (7,758,607 ) Denominator Weighted average shares - basic 973,656,518 214,830,818 932,959,287 166,814,645 Stock options - - Warrants - - Denominator for diluted loss per share 973,656,518 214,830,818 932,959,287 166,814,645 Loss per share - basic and diluted $ (0.005 ) $ (0.02 ) $ (0.04 ) $ (0.05 ) For the above‑mentioned periods, the Company had stock options and warrants outstanding which could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted loss per share in the periods presented, as their effect would have been anti‑dilutive.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Estimates and assumptions In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not may may may
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value. The Company utilizes specific identification to track inventory costs. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not
Revenue [Policy Text Block]	Revenue recognition The Company enters into agreements which may The Company allocates revenue to each performance obligation in proportion to the relative standalone selling prices and recognizes revenue when control of the related goods or services is transferred for each obligation. We utilize the observable standalone selling price when available, which represents the price charged for the performance obligation when sold separately. The Company's contracts with customers are generally comprised of purchase orders for the sale of the point of care diagnostic instrument, consumable products, and warranties, or some variation thereof. The instrument and consumables each represent a single performance obligation when sold separately, that is satisfied at a point in time upon transfer of control of the product to the customer which is typically upon receipt of the goods by the customer. The warranties are also a separate performance obligation, whereby revenue is recognized over time. Sales are recorded net of sales tax. Sales tax is charged on sales to end users and remitted to the appropriate state authority. Accounts receivable are recorded at net realizable value and have payment terms of 30
Cost of Goods and Service [Policy Text Block]	Cost of revenue Cost of goods sold consists of materials, and shipping costs incurred internally to produce and receive the products. Shipping and handling costs incurred by the Company are included in cost of goods sold.
Reclassification, Comparability Adjustment [Policy Text Block]	Comparative figures Certain prior year amounts have been reclassified to conform to the current year presentation. The change in presentation had no three six June 30, 2020. not

Note 4 - Prepaid Expenses, De_2

Note 4 - Prepaid Expenses, Deposits, and Deferred Financing Costs (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Prepaid Expenses and Deposits [Table Text Block]	June 30, December 31, 2021 2020 Deposits (i) $ 1,173,689 $ 1,469,043 Prepaid marketing 13,993 26,330 Prepaid insurance 33,995 184,154 Other (ii) 81,884 62,211 Total $ 1,303,561 $ 1,741,738

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30, December 31, 2021 2020 Computer equipment $ 409,825 $ 364,165 Furniture and equipment 110,244 121,281 Laboratory equipment 225,330 234,087 Leasehold improvements 272,192 571,460 1,017,591 1,290,993 Accumulated depreciation and amortization 751,745 707,986 Net property and equipment $ 265,845 $ 583,007

Note 6 - Intangible Assets (Tab

Note 6 - Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	June 30, December 31, 2021 2020 Computer software $ 28,097 $ 22,882 Trademarks 16,236 16,236 Website 609,121 513,680 653,454 552,798 Accumulated amortization 279,603 190,135 Net intangibles $ 373,851 $ 362,663

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Lessee, Operating Lease, Right of Use Asset and Lease Liabilities [Table Text Block]	June 30, 2021 December 31, 2020 Right-of-use asset Cost Aggregate lease commitments $ 1,387,655 $ 2,067,505 Less: impact of present value and lease modification (129,392 ) (513,894 ) Balance 1,258,263 1,553,611 Reduction in right-of-use asset Straight line amortization 142,116 379,043 Interest (16,400 ) (144,148 ) Balance 125,716 234,895 Net book value $ 1,132,548 $ 1,318,716 Lease liabilities Additions $ 1,281,609 $ 1,553,611 Payments (108,941 ) (356,972 ) Interest 16,400 144,147 Total lease liabilities $ 1,189,068 $ 1,340,786 Current portion of lease liabilities 302,112 252,788 Long term portion of lease liabilities 886,956 1,087,998 Total lease liabilities $ 1,189,068 $ 1,340,786
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2021 - remainder balance $ 169,728 $ 400,133 2022 348,790 412,137 2023 359,254 424,501 2024 370,031 437,236 2025 30,911 36,526 Total $ 1,278,714 $ 1,710,533

Note 9 - Preferred Shares (Tabl

Note 9 - Preferred Shares (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Preferred Stock [Table Text Block]	Number of preferred Preferred stock stock amount Balance at December 31, 2019 12 $ 11,961,397 Balance at December 31, 2020 12 11,961,397 Stock redemption (12 ) (11,961,397 ) Balance at June 30, 2021 - $ -

Note 10 - Common Shares (Tables

Note 10 - Common Shares (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Common Stock Outstanding Roll Forward [Table Text Block]	Number of common stock Common stock amount Balance at December 31, 2019 108,038,398 $ 38,566,820 Stock issued from financing (i,ii,iii) 175,330,001 14,074,182 Stock issued from the financing and exercise of prefunded warrants (iv) 12,162,492 1,080,289 Stock issued from the exercise of warrants 65,509,055 13,607,631 Balance at June 30, 2020 361,039,946 67,328,922 Balance at December 31, 2020 642,036,228 $ 104,783,612 Stock issued from financing (v) 105,013,158 185,244,086 Stock issued from exercises of warrants 200,951,905 44,082,183 Stock issued from exercises of options (Note 11) 5,230,601 2,112,210 Stock issued from preferred share redemption (Note 9) 24,719,101 44,000,000 Balance at June 30, 2021 977,950,993 $ 380,222,091
Class of Warrant or Right, Warrant Series [Table Text Block]	Warrant series Warrants exercised Amount Series A 21,677,084 $ 4,293,229 Series B 17,969,833 2,695,475 Series C 133,056,833 19,958,525 Series D 187,269,000 29,963,040 Subtotal 359,972,750 56,910,269 Common stock subscribed - (459,600 ) Total 359,972,750 $ 56,450,669

Note 11 - Stock-based Compens_2

Note 11 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted Avg Exercise Price Balance at December 31, 2020 39,604,515 $ 0.36 Stock options granted 9,200,000 $ 0.95 Stock options exercised (5,774,351 ) $ 0.26 Stock options forfeited (4,509,015 ) $ 1.36 Stock options cancelled (200,000 ) $ 1.87 Balance at June 30, 2021 38,321,149 $ 0.23 Vested at June 30, 2021 10,342,149 $ 0.27
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Grant date Exercise price Number of options issued and outstanding Number of vested options outstanding Number of unvested options outstanding Weighted Avg Remaining Life outstanding (years) March 14, 2020 0.19 3,253,557 1,900,807 1,352,750 3.71 July 9, 2020 0.18 175,000 43,750 131,250 4.03 August 25, 2020 0.13 38,425 8,425 30,000 4.16 September 29, 2020 0.11 225,000 225,000 - 4.16 October 1, 2020 0.11 266,667 41,667 225,000 4.16 October 20, 2020 0.09 40,000 10,000 30,000 4.31 December 31, 2020 0.23 25,322,500 7,762,500 17,560,000 9.51 February 26, 2021 1.87 600,000 150,000 450,000 9.67 March 1, 2021 2.06 200,000 50,000 150,000 9.67 March 8, 2021 1.88 200,000 50,000 150,000 9.69 March 15, 2021 2.49 200,000 50,000 150,000 9.71 May 12, 2021 0.78 4,600,000 - 4,600,000 9.87 May 14, 2021 0.78 3,200,000 50,000 3,150,000 9.88 Balance at June 30, 2021 38,321,149 10,342,149 27,979,000
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	March 14, 2020 February 26, 2021 March 1, 2021 March 8, 2021 Volatility 87 % 117 % 117 % 117 % Risk-free interest rate 0.49 % 0.95 % 0.92 % 1.07 % Expected life (years) 5 10 10 10 Dividend yield 0 % 0 % 0 % 0 % Common share price $ 0.18 $ 1.87 $ 2.06 $ 1.88 Strike price $ 0.19 $ 1.87 $ 2.06 $ 1.88 Forfeiture rate 0 0 0 0 March 15, 2021 May 12, 2021 Volatility 117 % 118 % Risk-free interest rate 1.06 % 1.11 % Expected life (years) 10 6.21 - 6.22 Dividend yield 0 % 0 % Common share price $ 2.49 $ 0.78 Strike price $ 2.49 $ 0.78 Forfeiture rate 0 0

Note 12 - Warrants (Tables)

Note 12 - Warrants (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Original Issue date Exercise Price Warrants Outstanding Weighted Average Remaining Life February 14, 2020 0.20 - - February 14, 2020 0.15 197,917 3.62 April 9, 2020 0.15 363,501 3.78 May 29, 2020 0.15 276,500 0.91 July 7, 2020 0.16 231,000 1.02 Balance at June 30, 2021 1,068,918

Note 14 - Financial Instrumen_2

Note 14 - Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities [Table Text Block]	June 30, 2021 Less than 3 6 6 9 9 months Greater than 3 months months months 1 year 1 year Total Third parties Accounts payable and accrued liabilities $ 3,095,203 $ - $ - $ - $ - $ 3,095,203 Lease obligations 73,362 74,089 76,524 78,137 886,956 1,189,068 $ 3,168,565 $ 74,089 $ 76,524 $ 78,137 $ 886,956 $ 4,284,271 December 31, 2020 Less than 3 6 6 9 9 months Greater than 3 months months months 1 year 1 year Total Third parties Accounts payable and accrued liabilities $ 1,248,628 $ - $ - $ - $ - $ 1,248,628 Debt obligations 527,360 - - - - 527,360 Lease obligations 59,662 62,463 64,356 66,307 1,087,998 1,340,786 $ 1,835,650 $ 62,463 $ 64,356 $ 66,307 $ 1,087,998 $ 3,116,774

Note 15 - Segment Information (

Note 15 - Segment Information (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Long-lived Assets by Geographic Areas [Table Text Block]	June 30, December 31, 2021 2020 Canada $ 249,894,586 $ 53,160,701 US 30,457,698 12,983,333 Total assets $ 280,352,284 $ 66,144,034 Total US property and equipment $ 265,845 $ 583,007 Total US right-of-use asset 1,132,548 1,318,716 $ 1,398,393 $ 1,901,723

Note 16 - Loss Per Share (Table

Note 16 - Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the three months ended June 30 For the six months ended June 30 2021 2020 2021 2020 Numerator Net loss for the period $ (4,710,674 ) $ (5,307,989 ) $ (8,747,491 ) $ (7,758,607 ) Charge to retained earnings for preferred share exchange - (32,038,603 ) - Loss attributable to common shareholders (4,710,674 ) (5,307,989 ) (40,786,094 ) (7,758,607 ) Denominator Weighted average shares - basic 973,656,518 214,830,818 932,959,287 166,814,645 Stock options - - Warrants - - Denominator for diluted loss per share 973,656,518 214,830,818 932,959,287 166,814,645 Loss per share - basic and diluted $ (0.005 ) $ (0.02 ) $ (0.04 ) $ (0.05 )

Note 4 - Prepaid Expenses, De_3

Note 4 - Prepaid Expenses, Deposits, and Deferred Financing Costs (Details Textual) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Prepaid Expenses and Deposits, Noncurrent	$ 1,081,083	$ 13,924

Note 4 - Prepaid Expenses, De_4

Note 4 - Prepaid Expenses, Deposits and Deferred Financing Costs - Summary of Prepaid Expenses, Deposits and Deferred Financing Costs (Details) - USD ($)		Jun. 30, 2021	Dec. 31, 2020
Deposits	[1]	$ 1,173,689	$ 1,469,043
Prepaid marketing		13,993	26,330
Prepaid insurance		33,995	184,154
Other	[2]	81,884	62,211
Total		$ 1,303,561	$ 1,741,738
[1]	Deposits include payments made to vendors in advance and are primarily associated with inventory, warranties, and research activity. As of June 30, 2021, and December 31, 2020, the Company classified $1,081,083 and $13,924 as a non-current asset, with the remainder classified as a current asset in the consolidated balance sheets.
[2]	Other is comprised of deferred financing costs, subscription payments, utilities, travel costs, and software licensing. As of June 30, 2021, and December 31, 2020, the Company classified all amounts as a current asset in the consolidated balance sheets.

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Depreciation, Total	$ 55,398	$ 77,859	$ 114,724	$ 154,275

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment - Property and Equipment (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Property and equipment, gross	$ 1,017,591	$ 1,290,993
Accumulated depreciation and amortization	751,745	707,986
Net property and equipment	265,845	583,007
Computer Equipment [Member]
Property and equipment, gross	409,825	364,165
Furniture and Fixtures [Member]
Property and equipment, gross	110,244	121,281
Laboratory Equipment [Member]
Property and equipment, gross	225,330	234,087
Leasehold Improvements [Member]
Property and equipment, gross	$ 272,192	$ 571,460

Note 6 - Intangible Assets (Det

Note 6 - Intangible Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Amortization of Intangible Assets, Total	$ 45,147	$ 44,990	$ 89,468	$ 90,025

Note 6 - Intangible Assets - Fi

Note 6 - Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Finite-lived intangible assets, gross	$ 653,454	$ 552,798
Accumulated amortization	279,603	190,135
Net intangibles	373,851	362,663
Computer Software, Intangible Asset [Member]
Finite-lived intangible assets, gross	28,097	22,882
Trademarks [Member]
Finite-lived intangible assets, gross	16,236	16,236
Website [Member]
Finite-lived intangible assets, gross	$ 609,121	$ 513,680

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) - USD ($)	Feb. 01, 2021	Feb. 01, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Increase (Decrease) in Prepaid Rent					$ 0	$ 1,002,113
Operating Lease, Right-of-Use Asset			$ 1,132,548		1,132,548		$ 1,318,716
Operating Lease, Liability, Total			1,189,068		1,189,068		$ 1,340,786
Lease Agreement with Wickfield Phoenix LLC [Member]
Lessee, Operating Lease, Term of Contract (Month)	48 months	60 months
Monthly Rent Payment		$ 36,525
Gain (loss) on Operating Lease, Right-of-Use Assets	$ 731
Operating Lease, Right-of-Use Asset	$ 1,281,609	$ 1,553,611
Lessee, Operating Lease, Discount Rate	3.95%	12.00%
Operating Lease, Right-of-Use Asset, Lease Modification	$ 1,258,263
Operating Lease, Liability, Total	1,281,609
Operating Lease, Expense			85,269	$ 145,823	176,154	172,291
Lease Agreement with Wickfield Phoenix LLC [Member] | Research and Development Expense [Member]
Operating Lease, Expense			17,053	21,763	37,798	38,992
Lease Agreement with Wickfield Phoenix LLC [Member] | General and Administrative Expense [Member]
Operating Lease, Expense			$ 68,216	$ 124,060	$ 138,776	$ 137,630
Lease Agreement with Wickfield Phoenix LLC [Member] | Minimum [Member]
Monthly Rent Payment	12,039	$ 32,452
Lease Agreement with Wickfield Phoenix LLC [Member] | Maximum [Member]
Monthly Rent Payment	$ 30,911
Lease Cancellation [Member]
Increase (Decrease) in Prepaid Rent		1,002,113
Operating Lease, Right-of-Use Asset, Lease Cancellation		1,061,210
Lease Modification [Member]
Gain (loss) on Operating Lease, Right-of-Use Assets		$ (59,097)

Note 7 - Leases - Right of Use

Note 7 - Leases - Right of Use Asset and Lease Liabilities (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Aggregate lease commitments	$ 1,387,655	$ 2,067,505
Less: impact of present value and lease modification	(129,392)	(513,894)
Cost, balance	1,258,263	1,553,611
Straight line amortization	142,116	379,043
Interest	(16,400)	(144,148)
Reduction in right-of-use asset, balance	125,716	234,895
Additions	1,281,609	1,553,611
Payments	(108,941)	(356,972)
Interest	16,400	144,147
Total lease liabilities	1,189,068	1,340,786
Current portion of lease liabilities	302,112	252,788
Long term portion of lease liabilities	$ 886,956	$ 1,087,998

Note 7 - Leases - Remaining Und

Note 7 - Leases - Remaining Undiscounted Lease Liabilities (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
2021 - remainder balance	$ 169,728	$ 400,133
2022	348,790	412,137
2023	359,254	424,501
2024	370,031	437,236
2025	30,911	36,526
Total	$ 1,278,714	$ 1,710,533

Note 8 - Loan Arrangements (Det

Note 8 - Loan Arrangements (Details Textual) - USD ($)	Jun. 13, 2021	Oct. 18, 2017	Apr. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Long-term Debt, Total								$ 527,360
Gain (Loss) on Extinguishment of Debt, Total				$ 533,414	$ 0	$ 533,414	$ 0
Loan Arrangement With Shareholder [Member]
Debt Agreement, Maximum Borrowing Capacity		$ 5,000,000
Debt Instrument, Term (Year)		5 years
Debt Agreement, Minimum Borrowing Per Advances		$ 250,000
Debt Instrument, Interest Rate, Stated Percentage		14.00%
Long-term Debt, Total				$ 0		$ 0
Paycheck Protection Program CARES Act [Member]
Proceeds from Short-term Debt, Total			$ 527,360
Gain (Loss) on Extinguishment of Debt, Total	$ 533,414
Gain (Loss) on Extinguishment of Debt, Portion Attributable to Accrued Interest	$ 6,054

Note 9 - Preferred Shares (Deta

Note 9 - Preferred Shares (Details Textual) - USD ($)	Mar. 07, 2021	Jun. 30, 2021
Conversion of Stock, Amount Issued		$ 11,961,397
Redemption of Preferred Shares for Common Shares [Member]
Conversion of Stock, Shares Issued (in shares)	24,719,101
Conversion of Stock, Amount Issued	$ 44,000,000
Series 1 Preferred Shares [Member]
Preferred Stock, Shares Authorized (in shares)		20
Preferred Stock, Stated Value Per Share (in dollars per share)		$ 1,000,000
Net Sales Payments, Percentage of Sales		9.00%

Note 9 - Preferred Shares - Iss

Note 9 - Preferred Shares - Issued and Outstanding Preferred Stock (Details) - Series 1 Preferred Shares [Member] - USD ($)	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Balance, number (in shares)	0	12	12
Balance, amount	$ 0	$ 11,961,397	$ 11,961,397
Stock redemption (in shares)	(12)
Stock redemption	$ (11,961,397)

Note 10 - Common Shares (Detail

Note 10 - Common Shares (Details Textual) - USD ($)	Feb. 08, 2021	May 29, 2020	Apr. 09, 2020	Feb. 14, 2020	Jun. 30, 2020	Feb. 29, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jul. 07, 2020
Issuance of Common Shares and Warrants, Direct Costs of Issuance	$ 14,281,368	$ 1,908,202	$ 582,977			$ 348,220	$ 453	$ (2,491,180)	$ (14,280,914)	$ (2,839,400)
Adjustments to Equity, Warrant Issued								0		0
Proceeds from Issuance of Common Stock									199,525,000	26,498,783
Stock Issued During Period, Shares, Exercise of Warrants and Pre-funded Warrants (in shares)					12,162,492
Common Stock [Member]
Stock Issued During Period, Value, New Issues	$ 199,525,000
Issuance of Common Shares and Warrants, Direct Costs of Issuance		1,088,876	428,283			238,217	453	(1,517,159)	(14,280,914)	(1,755,376)
Adjustments to Equity, Warrant Issued								$ (118,951)		$ (154,767)
Stock Issued During Period, Shares, Exercise of Warrants and Pre-funded Warrants (in shares)								77,671,547		77,671,547
Additional Paid-in Capital [Member]
Issuance of Common Shares and Warrants, Direct Costs of Issuance		$ 819,327	$ 154,694			110,003	$ 0	$ (974,021)	$ 0	$ (1,084,024)
Adjustments to Equity, Warrant Issued								$ 118,951		$ 154,767
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				20,833,334
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.20
Class of Warrant or Right, Period Exerciseable (Month)				6 months
Warrants and Rights Outstanding, Term (Year)				5 years 6 months
Class of Warrant or Right, Issued During Period (in shares)				20,833,334
Class of Warrant or Right, Issued During Period, Value				$ 794,345
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,666,667	1,041,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15	$ 0.15
Warrants and Rights Outstanding, Term (Year)			5 years	5 years
Class of Warrant or Right, Issued During Period (in shares)			1,666,667	1,041,667
Adjustments to Equity, Warrant Issued			$ 161,714			52,496
Placement Agent Warrants [Member] | Common Stock [Member]
Adjustments to Equity, Warrant Issued			118,951			35,816
Placement Agent Warrants [Member] | Additional Paid-in Capital [Member]
Adjustments to Equity, Warrant Issued			$ 42,763			$ 16,680
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			16,666,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15
Warrants and Rights Outstanding, Term (Year)			5 years
Class of Warrant or Right, Issued During Period (in shares)			16,666,667
Proceeds from Issuance of Warrants			$ 1,057,752
Series C Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		133,333,333
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.15
Warrants and Rights Outstanding, Term (Year)		2 years
Class of Warrant or Right, Issued During Period (in shares)		133,333,333
Proceeds from Issuance of Warrants		$ 7,582,072
Pre-funded Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.0001
Class of Warrant or Right, Issued During Period (in shares)		12,170,000
Proceeds from Issuance of Warrants		$ 1,080,289
Public Offering with One Pre-funded Warrant and One Series C Warrant [Member]
Offering Price (in dollars per share)		$ 0.1499
Registered Direct Offering [Member]
Shares Issued, Number of Common Shares Per Share (in shares)				1
Stock Issued During Period, Shares, New Issues (in shares)				20,833,334
Shares Issued, Price Per Share (in dollars per share)				$ 0.12
Proceeds from Issuance or Sale of Equity, Total				$ 2,500,000
Stock Issued During Period, Value, New Issues				$ 1,705,655
Public Offering [Member]
Shares Issued, Number of Common Shares Per Share (in shares)		1	1								1
Stock Issued During Period, Shares, New Issues (in shares)		121,163,333
Proceeds from Issuance or Sale of Equity, Total		$ 19,998,783	$ 4,000,000
Stock Issued During Period, Value, New Issues		$ 11,336,422
Stock and Warrants Issued During Period, Shares, New Issues (in shares)			33,333,334
Shares Issued, Number of Warrants Per Share (in shares)			0.5
Offering Price (in dollars per share)			$ 0.12
Proceeds from Issuance of Common Stock			$ 2,942,248
Public Offering with One Common Share and One Series C Warrant [Member]
Offering Price (in dollars per share)		$ 0.15
The Common Shares Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	91,315,790
Shares Issued, Price Per Share (in dollars per share)	$ 1.90
Proceeds from Issuance of Common Stock	$ 199,525,000
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)	13,697,368

Note 10 - Common Shares - Issue

Note 10 - Common Shares - Issued and Outstanding Common Shares (Details) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021		Jun. 30, 2020
Stock issued from warrant exercises		$ 100,465		$ 32,111,537
Number of common shares (in shares)				642,036,228
Stock issued from stock option exercises (in shares)				5,230,601
Stock issued from stock option exercises		$ 1,367,803	$ 0	$ 1,367,803		$ 0
Stock issued from preferred share redemption (Note 9)				$ 11,961,397
Number of common shares (in shares)		977,950,993		977,950,993
Common Stock [Member]
Stock issued from financing (in shares)				105,013,158	[1]	175,330,001	[2],[3],[4]
Stock issued from financing				$ 185,244,086	[1]	$ 14,074,182	[2],[3],[4]
Stock issued from the financing and exercise of prefunded warrants (in shares)	[5]					12,162,492
Stock issued from the financing and exercise of prefunded warrants	[5]					$ 1,080,289
Stock issued from warrant exercises (in shares)		628,084		200,951,905		65,509,055
Stock issued from warrant exercises		$ 138,582		$ 44,082,183		$ 13,607,631
Number of common shares (in shares)				642,036,228
Capital stock				$ 104,783,612
Stock issued from stock option exercises (in shares)		5,230,601		5,230,601
Stock issued from stock option exercises		$ 2,112,210		$ 2,112,210
Stock issued from preferred share redemption (Note 9) (in shares)				24,719,101
Stock issued from preferred share redemption (Note 9)				$ 44,000,000
Number of common shares (in shares)		977,950,993	361,039,946	977,950,993		361,039,946
Capital stock		$ 380,222,091	$ 67,328,922	$ 380,222,091		$ 67,328,922
[1]	On February 8, 2021, the Company completed a sale of 91,315,790 common shares at an offering price of $1.90 per share. The company also granted the underwriter a 30-day option to purchase up to 13,697,368 additional common shares at the public offering price. The Company raised $199,525,000 in gross proceeds as part of the offering. The Company recorded $199,525,000 as the value of common shares under common shares. The direct cash costs related to the issuance of the common shares and warrants issued in February 2021 were $14,281,368. These direct costs were recorded as an offset against the statement of shareholders’ equity with the entirety recorded under common shares.
[2]	On April 9, 2020, the Company completed a confidentially marketed public offering (“CMPO”) of its common shares and warrants (“Series B Warrants”) of 33,333,334 common shares and warrants to purchase up to 16,666,667 common shares. The securities were sold in a fixed combination of one common share and 0.5 of a Series B Warrant at a combined offering price of $0.12 per share and accompanying warrant. Each whole warrant is exercisable immediately for one common share after issuance, at an exercise price of $0.15 per share and has a term of 5 years. The Company also issued warrants to the placement agents to purchase 1,666,667 common shares at an exercise price of $0.15 per share (“Series B Placement Agent Warrants”), which were exercisable immediately upon issuance and have a term of 5 years. In aggregate, the Company issued 33,333,334 common shares,16,666,667 Series B Warrants in addition to 1,666,667 Series B Placement Agent Warrants. The Company raised $4,000,000 in gross proceeds in the CMPO. The Company recorded $2,942,248 as the value of common shares under common stock and $1,057,752 as the value of Series B Warrants under additional paid-in-capital in the consolidated statements of shareholders’ equity. The direct cash costs related to the issuance of the common shares and warrants issued in April were $582,977. These direct costs were recorded as an offset against the statement of shareholders’ equity with $428,283 being recorded under capital stock and $154,694 being recorded under additional paid-in-capital. The Company also recorded the value of the Series B Placement Agent Warrants in the amount of $161,714 as an offset against the statement of shareholders’ equity with $118,951 being recorded under capital stock and $42,763 being recorded under additional paid-in-capital.
[3]	On February 14, 2020, the Company completed a registered direct offering (“RDO”) of its common shares and a simultaneous private placement of its warrants (“Series A Warrants”) in a fixed combination of one common share and a Series A Warrant to purchase one common share, resulting in the sale of 20,833,334 common shares and Series A Warrants to purchase 20,833,334 common shares at a combined offering price of $0.12 per share and related Series A Warrant. Each Series A Warrant has an exercise price of $0.20 per share, is exercisable six months after issuance and has a term of 5.5 years. The Company also issued warrants to the placement agents to purchase 1,041,667 common shares at an exercise price of $0.15 per share (“Placement Agent Warrants”), which were exercisable immediately upon issuance and have a term of 5 years. In aggregate, the Company issued 20,833,334 common shares, 20,833,334 Series A Warrants, and an additional 1,041,667 Series A Placement Agent Warrants. The Company raised $2,500,000 in gross proceeds as part of the RDO. The Company recorded $1,705,655 as the value of common shares under common shares and $794,345 as the value of Series A Warrants under additional paid-in-capital in the consolidated statements of shareholders’ equity. The direct cash costs related to the issuance of the common shares and warrants issued in February 2020 were $348,220. These direct costs were recorded as an offset against the statement of shareholders’ equity with $238,217 being recorded under common shares and $110,003 being recorded under additional paid-in-capital. The Company also recorded the value of the Series A Placement Agent Warrants in the amount of $52,496 as an offset against the statement of shareholders’ equity with $35,816 being recorded under common shares and $16,680 being recorded under additional paid-in-capital.
[4]	On May 29, 2020 the Company completed a public offering of its common shares or common share equivalents (“Series C pre-funded warrants”), and warrants (“Series C Warrants”) in a fixed combination of one common share or Series C pre-funded warrant, and a Series C Warrant to purchase one common share, resulting in the sale of 121,163,333 common shares, 12,170,000 pre-funded warrants, and Series C Warrants to purchase 133,333,333 common shares at a combined offering price of $0.15 per share for the common shares and related Series C Warrant, or a combined offering price of $0.1499 per pre-funded warrant and related Series C warrant. Each Series C pre-funded warrant has an exercise price of $0.0001 per share, is exercisable immediately after issuance, is exercisable only on a cashless exercise basis, and will not expire prior to exercise. Each Series C Warrant has an exercise price of $0.15 per share, is exercisable immediately after issuance and has a term of 2 years. The Company raised $19,998,783 in gross proceeds as part of the public offering. The Company recorded $11,336,422 as the value of common shares under common stock, $1,080,289 as the value of the pre-funded warrants and $7,582,072 as the value of Series C Warrants under additional paid-in-capital in the consolidated statements of shareholders’ equity. The direct cash costs related to the issuance of the common shares, Series C pre-funded warrants and Series C Warrants issued in May were $1,908,202. These direct costs were recorded as an offset against the statement of shareholders’ equity with $1,088,876 being recorded under capital stock and $819,327 being recorded under additional paid-in-capital.
[5]	All Series C pre-funded warrants were exercised in June 2020. Upon exercise the value of the warrant exercise was based on the one-day VWAP of the Company stock the day before the exercise request date. The cashless exercise option resulted in the issuance of 12,162,492 shares.

Note 10 - Common Shares - Warra

Note 10 - Common Shares - Warrant Exercises (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Class of warrant or right, warrants exercised (in shares)	359,972,750
Class of warrant or right, warrants exercised, value	$ 56,910,269
Common stock subscribed, value	0	$ (459,600)
Class of warrant or right, warrants exercised, total value	$ 56,450,669
Series A Warrants [Member]
Class of warrant or right, warrants exercised (in shares)	21,677,084
Class of warrant or right, warrants exercised, value	$ 4,293,229
Series B Warrants [Member]
Class of warrant or right, warrants exercised (in shares)	17,969,833
Class of warrant or right, warrants exercised, value	$ 2,695,475
Series C Warrants [Member]
Class of warrant or right, warrants exercised (in shares)	133,056,833
Class of warrant or right, warrants exercised, value	$ 19,958,525
Series D Warrants [Member]
Class of warrant or right, warrants exercised (in shares)	187,269,000
Class of warrant or right, warrants exercised, value	$ 29,963,040

Note 11 - Stock-based Compens_3

Note 11 - Stock-based Compensation (Details Textual) - USD ($)	Jul. 01, 2021	Jul. 01, 2021	Jun. 30, 2021	Jun. 30, 2020	Jul. 01, 2021	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			7,800,000	5,056,000		9,200,000	5,056,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)						4 years	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)						10 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)						5,230,601
Proceeds from Stock Options Exercised			$ 1,367,802	$ 0		$ 1,367,802	$ 0
Stock Issued During Period, Value, Stock Options Exercised			1,367,803	0		1,367,803	0
Share-based Payment Arrangement, Expense			1,782,076	$ 135,844		3,064,818	$ 290,866
Additional Paid-in Capital [Member]
Stock Issued During Period, Value, Stock Options Exercised			$ (744,407)			$ (744,407)
Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)	543,750	5,774,351			5,774,351

Note 11 - Stock-based Compens_4

Note 11 - Stock-based Compensation - Issuance of Stock Options (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Number of Options, Options Outstanding (in shares)			39,604,515
Weighted Avg Exercise Price, Options Outstanding (in dollars per share)			$ 0.36
Number of Options, Stock options granted (in shares)	7,800,000	5,056,000	9,200,000	5,056,000
Weighted Avg Exercise Price, Stock options granted (in dollars per share)			$ 0.95
Stock options exercised (in shares)			(5,774,351)
Weighted Avg Exercise Price, Stock options exercised (in dollars per share)			$ 0.26
Number of Options, Stock options forfeited (in shares)			(4,509,015)
Weighted Avg Exercise Price, Stock options forfeited (in dollars per share)			$ 1.36
Number of Options, Stock options cancelled (in shares)			(200,000)
Weighted Avg Exercise Price, Stock options cancelled (in dollars per share)			$ 1.87
Number of Options, Options Outstanding (in shares)	38,321,149		38,321,149
Weighted Avg Exercise Price, Options Outstanding (in dollars per share)	$ 0.23		$ 0.23
Number of Options, Options Vested (in shares)	10,342,149		10,342,149
Weighted Avg Exercise Price, Vested (in dollars per share)	$ 0.27		$ 0.27

Note 11 - Stock-based Compens_5

Note 11 - Stock-based Compensation - Details of the Issued Stock Options (Details) - $ / shares	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.95
Number of Options (in shares)	38,321,149	39,604,515
Number of unvested options outstanding (in shares)	27,979,000
Number of Options, Options Vested (in shares)	10,342,149
March 14, 2020 [Member] | Options 1 [Member]
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.19
Number of Options (in shares)	3,253,557
Number of Vested Options (in shares)	1,900,807
Number of unvested options outstanding (in shares)	1,352,750
Weighted Avg Remaining Life (Year)	3 years 8 months 15 days
July 9, 2020 [Member] | Options 2 [Member]
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.18
Number of Options (in shares)	175,000
Number of Vested Options (in shares)	43,750
Number of unvested options outstanding (in shares)	131,250
Weighted Avg Remaining Life (Year)	4 years 10 days
August 25, 2020 [Member] | Options 3 [Member]
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.13
Number of Options (in shares)	38,425
Number of Vested Options (in shares)	8,425
Number of unvested options outstanding (in shares)	30,000
Weighted Avg Remaining Life (Year)	4 years 1 month 28 days
September 29, 2020 [Member] | Options 4 [Member]
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.11
Number of Options (in shares)	225,000
Number of Vested Options (in shares)	225,000
Number of unvested options outstanding (in shares)	0
Weighted Avg Remaining Life (Year)	4 years 1 month 28 days
October 1, 2020 [Member] | Option 5 [Member]
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.11
Number of Options (in shares)	266,667
Number of Vested Options (in shares)	41,667
Number of unvested options outstanding (in shares)	225,000
Weighted Avg Remaining Life (Year)	4 years 1 month 28 days
October 20, 2020 [Member] | Option 6 [Member]
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.09
Number of Options (in shares)	40,000
Number of Vested Options (in shares)	10,000
Number of unvested options outstanding (in shares)	30,000
Weighted Avg Remaining Life (Year)	4 years 3 months 21 days
December 31, 2020 [Member] | Option 7 [Member]
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.23
Number of Options (in shares)	25,322,500
Number of Vested Options (in shares)	7,762,500
Number of unvested options outstanding (in shares)	17,560,000
Weighted Avg Remaining Life (Year)	9 years 6 months 3 days
February 26, 2021 [Member] | Options 16 [Member]
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 1.87
Number of Options (in shares)	600,000
Number of unvested options outstanding (in shares)	450,000
Weighted Avg Remaining Life (Year)	9 years 8 months 1 day
Number of Options, Options Vested (in shares)	150,000
March 1, 2021 [Member] | Option 8 [Member]
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 2.06
Number of Options (in shares)	200,000
Number of Vested Options (in shares)	50,000
Number of unvested options outstanding (in shares)	150,000
Weighted Avg Remaining Life (Year)	9 years 8 months 1 day
March 8, 2021 [Member] | Option 9 [Member]
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 1.88
Number of Options (in shares)	200,000
Number of unvested options outstanding (in shares)	150,000
Weighted Avg Remaining Life (Year)	9 years 8 months 8 days
Number of Options, Options Vested (in shares)	50,000
March 15, 2021 [Member] | Option 10 [Member]
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 2.49
Number of Options (in shares)	200,000
Number of unvested options outstanding (in shares)	150,000
Weighted Avg Remaining Life (Year)	9 years 8 months 15 days
Number of Options, Options Vested (in shares)	50,000
May 12, 2021 [Member] | Option 11 [Member]
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.78
Number of Options (in shares)	4,600,000
Number of unvested options outstanding (in shares)	4,600,000
Weighted Avg Remaining Life (Year)	9 years 10 months 13 days
Number of Options, Options Vested (in shares)	0
May 14, 2021 [Member] | Option 12 [Member]
Weighted Avg Exercise Price, Stock options granted (in dollars per share)	$ 0.78
Number of Options (in shares)	3,200,000
Number of unvested options outstanding (in shares)	3,150,000
Weighted Avg Remaining Life (Year)	9 years 10 months 17 days
Number of Options, Options Vested (in shares)	50,000

Note 11 - Stock-based Compens_6

Note 11 - Stock-based Compensation - Valuation Assumptions for Fair Value of Options Granted (Details) - $ / shares	May 12, 2021	Mar. 15, 2021	Mar. 08, 2021	Mar. 01, 2021	Feb. 26, 2021	Mar. 14, 2020
Volatility			117.00%	117.00%	117.00%	87.00%
Risk-free interest rate			1.07%	0.92%	0.95%	0.49%
Expected life (years) (Year)			10 years	10 years	10 years	5 years
Dividend yield			0.00%	0.00%	0.00%	0.00%
Common share price (in dollars per share)			$ 1.88	$ 2.06	$ 1.87	$ 0.18
Strike price (in dollars per share)			$ 1.88	$ 2.06	$ 1.87	$ 0.19
Forfeiture rate			0.00%	0.00%	0.00%	0.00%
Options 1 [Member]
Volatility		117.00%
Risk-free interest rate		1.06%
Expected life (years) (Year)		10 years
Dividend yield		0.00%
Common share price (in dollars per share)		$ 2.49
Strike price (in dollars per share)		$ 2.49
Forfeiture rate		0.00%
Options 2 [Member]
Volatility	118.00%
Risk-free interest rate	1.11%
Dividend yield	0.00%
Common share price (in dollars per share)	$ 0.78
Strike price (in dollars per share)	$ 0.78
Forfeiture rate	0.00%
Options 2 [Member] | Minimum [Member]
Expected life (years) (Year)	6 years 2 months 15 days
Options 2 [Member] | Maximum [Member]
Expected life (years) (Year)	6 years 2 months 19 days

Note 12 - Warrants (Details Tex

Note 12 - Warrants (Details Textual) - $ / shares	Jul. 07, 2020	May 29, 2020	Apr. 09, 2020	Feb. 14, 2020
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				20,833,334
Warrants and Rights Outstanding, Term (Year)				5 years 6 months
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.20
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			1,666,667	1,041,667
Warrants and Rights Outstanding, Term (Year)			5 years	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15	$ 0.15
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			16,666,667
Warrants and Rights Outstanding, Term (Year)			5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15
Series C Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		133,333,333
Warrants and Rights Outstanding, Term (Year)		2 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.15
Series C Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		12,170,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.0001
Series D Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	187,500,000
Warrants and Rights Outstanding, Term (Year)	2 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.16
Series D Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	25,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.0001

Note 12 - Warrants - Details of

Note 12 - Warrants - Details of Outstanding Warrants (Details)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Warrants and Rights, Outstanding (in shares)	1,068,918
Warrant One [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.20
Warrants and Rights, Outstanding (in shares)	0
Warrant Two [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.15
Warrants and Rights, Outstanding (in shares)	197,917
Warrants, weighted average remaining life (Year)	3 years 7 months 13 days
Warrant Three [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.15
Warrants and Rights, Outstanding (in shares)	363,501
Warrants, weighted average remaining life (Year)	3 years 9 months 10 days
Warrant Four [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.15
Warrants and Rights, Outstanding (in shares)	276,500
Warrants, weighted average remaining life (Year)	10 months 28 days
Warrant Five [Member]
Warrant, exercise price (in dollars per share) | $ / shares	$ 0.16
Warrants and Rights, Outstanding (in shares)	231,000
Warrants, weighted average remaining life (Year)	1 year 7 days

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Details Textual) - Seraph Biosciences, Inc. [Member]	May 10, 2018USD ($)
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Cash	$ 3,500,000
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Equity	$ 3,500,000

Note 14 - Financial Instrumen_3

Note 14 - Financial Instruments - Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Accounts payable and Accrued Liabilities, maturity less than 3 Months	$ 3,095,203	$ 1,248,628
Accounts payable and accrued liabilities, Maturity 3 to 6 Months	0	0
Accounts payable and accrued liabilities, Maturity 6 to 9 Months	0	0
Accounts payable and accrued liabilities, Maturity 9 to 12 Months	0
Accounts payable and accrued liabilities, Greater than 1 Year	0	0
Accounts payable and accrued liabilities	3,095,203	1,248,628
Lease obligations, maturity less than 3 Months	73,362	59,662
Lease obligations, Maturity 3 to 6 Months	74,089	62,463
Lease obligations, Maturity 6 to 9 Months	76,524	64,356
Lease obligations, Maturity 9 to 12 Months	78,137	66,307
Long term portion of lease liabilities	886,956	1,087,998
Total lease liabilities	1,189,068	1,340,786
Maturity Less Than 3 Months	3,168,565	1,835,650
Maturity 3 to 6 Months	74,089	62,463
Maturity 6 to 9 Months	76,524	64,356
Maturity 9 to 12 Months	78,137	66,307
Maturity Greater Than 1 Year	886,956	1,087,998
Liabilities, Total	$ 4,284,271	3,116,774
Debt obligations, maturity less than 3 Months		527,360
Debt obligations, Maturity 3 to 6 Months		0
Debt obligations, Maturity 6 to 9 Months		0
Debt obligations, Maturity 9 to 12 Months		0
Debt obligations, Maturity Greater Than 1 Year		0
Debt obligations		$ 527,360

Note 15 - Segment Information -

Note 15 - Segment Information - Long-lived Assets by Geographic Areas (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Assets	$ 280,352,284	$ 66,144,034
Total US property and equipment	265,845	583,007
Total US right-of-use asset	1,132,548	1,318,716
Property, Plant and Equipment, Including Leased Assets	1,398,393	1,901,723
CANADA
Assets	249,894,586	53,160,701
UNITED STATES
Assets	30,457,698	12,983,333
Total US property and equipment	$ 265,845	$ 583,007

Note 16 - Loss Per Share - Loss

Note 16 - Loss Per Share - Loss Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net loss	$ (4,710,674)	$ (5,307,989)	$ (8,747,491)	$ (7,758,607)
Charge to retained earnings for preferred share exchange	0		(32,038,603)	0
Loss attributable to common shareholders	$ (4,710,674)	$ (5,307,989)	$ (40,786,094)	$ (7,758,607)
Weighted average shares - basic (in shares)	973,656,518	214,830,818	932,959,287	166,814,645
Stock options (in shares)	0		0
Warrants (in shares)	0		0
Denominator for diluted loss per share (in shares)	973,656,518	214,830,818	932,959,287	166,814,645
Loss per share - basic and diluted (in dollars per share)	$ (0.005)	$ (0.02)	$ (0.04)	$ (0.05)